What is ACE-031?
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
Mechanism of Action
Soluble activin receptor type IIB extracellular domain fused to IgG1-Fc acts as a ligand trap for myostatin (GDF-8), activins, and related ligands; removes myostatin’s brake on muscle satellite-cell activation and fiber hypertrophy; off-target BMP9 binding implicated in vascular adverse events
Target: Myostatin (GDF-8), activins, and other ActRIIB ligands; BMP9 (off-target safety concern)
Research Indications
Demonstrated acceleration of wound healing and soft tissue repair in research
Research shows beneficial effects on intestinal lining and GI function
Associated with reduced joint inflammation and improved mobility
May support faster recovery from muscle strains and exercise stress
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Phase 1 Trial Context (healthy volunteers) | 0.02–3 mg/kg range studied; lean-mass signal at low-mg SubQ | Single ascending dose / infrequent | Subcutaneous injection |
| DMD Trial Context | Protocol-defined mg SubQ (development halted) | Every 2–4 weeks in trial schedules | Subcutaneous injection |
| Evidence Boundary | No approved or recommended consumer dose | Do not self-titrate — development stopped for safety | Qualified laboratory/professional protocol only |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove ACE-031 vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.
Week 2–4
Improved tissue mobility and reduced discomfort. Early healing acceleration.
Week 4–8
Significant recovery milestones. Stronger tissue repair and functional improvement.
Week 8–12
Near-complete healing in many cases. Improved strength and tissue integrity.
Side Effects & Safety
- Bleeding-related adverse events — notably epistaxis (nosebleeds) and telangiectasias — that halted clinical development
- Vascular remodeling effects attributed to off-target BMP9 inhibition
- Increased bleeding risk when combined with anticoagulants, antiplatelets, or NSAIDs
- Injection site reactions (redness, bruising, discomfort)
- Human safety is not established — development was discontinued for safety and there is no approved dose
FDA Status & Regulatory Info
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
Frequently Asked Questions
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
What 308 users report
Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 22% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 68 repeat reporters
Share Your Experience
Rate ACE-031 in the PeptIQ app and help the community make informed decisions.
Research References (4)
Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.
- Wiki study page →Source
PubMed
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie KM, Borgstein NG, Yang Y, et al. Muscle Nerve. 2013
- Wiki study page →Source
PubMed
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell C, McMillan HJ, Mah JK, et al. Muscle Nerve. 2017
- Wiki study page →Source
PubMed
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig MH, Ahmad K, Moon JS, et al. Front Physiol. 2022
- Wiki study page →Source
ClinicalTrials.gov
ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
Wiki tools
Observational indexes and compare views for ACE-031.
Educational information only
This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.